Please login to the form below

Neurofibromatosis: a condition that’s hard to say, but even harder to live with

The Childhood Tumour Trust and Havas Lynx Group have launched a campaign to raise awareness and funds for people living with a rare genetic condition, neurofibromatosis 1 (NF1).

The Childhood Tumour Trust and Havas Lynx Group have launched a campaign to raise awareness and funds for people living with a rare genetic condition, neurofibromatosis 1 (NF1).

As part of the Health For All initiative from Havas Lynx Group - aiming to change inequality within healthcare by removing bias and stereotypes, shifting misconceptions, and challenging stigma – The Childhood Tumour Trust and Havas Lynx Group are aiming to get people talking about a condition that you’ll struggle to even pronounce.

NF1 is a genetic condition causing tumours to grow on nerve endings in children and young people, its symptoms can have a huge physical and psychological impact on those affected. It’s more prevalent than Cystic Fibrosis, Duchenne Muscular Dystrophy, and Huntington’s Disease combined – yet is much less known.

The campaign ‘Hard to say’ aims to change this. By showing unusual ways in which NF1 can sometimes be mispronounced, the campaign aims to put NF1 in the spotlight to raise awareness and funds to help those living with the condition.

“This is a really innovative and interesting campaign and has the potential to really propel neurofibromatosis to be a household name, increased visibility of NF1 is so vital to people living with the condition and those that support them.”

Dr Carly Jim, trustee of CTT and Senior Lecturer in Psychology at Manchester Metropolitan University

“One of the first problems we realised when trying to get people talking about NF1 was the name itself. By creating a campaign that faces this head on, we hope to finally raise some much-needed awareness for NF1. The more we can get people talking about the condition, the more we can help those affected by it.”

John McPartland – Creative Director Havas Lynx Group

About Childhood Tumour Trust

Childhood Tumour Trust is a growing charity whose aim is to bring children, young people and their families affected by neurofibromatosis type 1 (NF1) together, (be it virtually at the moment), provide online parental support, campaign for better care & earlier diagnosis and to liaise with schools over special educational support.

20th October 2020

Share

Tags

Company Details

Havas Lynx Group

+44 (0)161 228 7756

Contact Website

Address:
52 Princess Street
Manchester
M1 6JX

Latest content on this profile

Havas Lynx Group launches proprietary data product to drive meaningful change across pharma
Leading global healthcare communications agency, Havas Lynx Group, has launched its proprietary data platform, Point.1, to help pharmaceutical companies to gain a deeper understanding of healthcare professionals (HCPs) to drive meaningful change across the industry.
Havas Lynx Group
Healing the Healers
Because if we do not heal the healers, who is going to heal us?
Havas Lynx Group
THE HIDDEN LIFESAVERS: overdose prevention campaign launches nationwide
The campaign encourages people who use drugs to do something remarkable – save a life
Havas Lynx Group
Andi Goes – the children’s book that helps detect early signs of dyslexia
Havas Lynx Group have launched a children’s book aimed at raising awareness and detecting early signs of dyslexia. Helping to make sure that parents have the support they need whilst teaching from home.
Havas Lynx Group
Neurofibromatosis: a condition that’s hard to say, but even harder to live with
The Childhood Tumour Trust and Havas Lynx Group have launched a campaign to raise awareness and funds for people living with a rare genetic condition, neurofibromatosis 1 (NF1).
Havas Lynx Group
Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
Havas Health & You (HH&Y) have launched the details of a long-term global research project, Behind the Mask, a longitudinal, multi-armed study which focuses on documenting the ongoing evolution of health and wellness.
Havas Lynx Group